Rep. Gilbert Cisneros (D-CA) Buys Boston Scientific (BSX) Stock
A new congressional disclosure shows Representative Gilbert Cisneros bought shares of the medical device maker in late May.
Reviewed by automated data checks against the source filing. How we make and check alerts
Rep. Gilbert Cisneros (D-CA) bought between $1,001 and $15,000 of Boston Scientific Corporation ($BSX) stock on May 29, 2026. The trade was disclosed in a STOCK Act periodic transaction report filed June 9, 2026.
Since the trade, $BSX is up 0.5% after 1 week, down 10.0% after 1 month and down 8.1% to date (from the $48.31 close on May 29, 2026).
Financial Disclosure Report
Clerk of the House of Representatives • Legislative Resource Center • B81 Cannon Building • Washington, DC 20515
Filer Information
- Name:
- Rep. Gilbert Cisneros (D-CA)
- Status:
- Member — House
- State/District:
- CA-31
- Party:
- democrat
Filing Information
- Filing Type:
- Periodic Transaction Report
- Filing Year:
- 2026
- Filing Date:
- Jun 9, 2026
Schedule B: Transactions
| Asset | Transaction | Date | Amount |
|---|---|---|---|
| Boston Scientific Corporation ($BSX) | Buy | May 29, 2026 | $1,001 - $15,000 |
Summary of the filed report, not the original document. Find the original: House financial disclosure search
BSX
Boston Scientific Corporation
Key Points
- U.S. House Representative Gilbert Cisneros disclosed a purchase of Boston Scientific stock valued between $1,001 and $15,000, with the trade occurring on May 29, 2026.
- The medical device company reported $20.99 billion in revenue and a net margin of 17.5%, while the stock currently trades near $42.84.
- Wall Street analysts remain largely positive on the stock, with firms like Truist Securities and BTIG maintaining Buy ratings despite recent price target adjustments.
Get $BSX trade alerts by text
We text you when insiders, Congress or big funds trade $BSX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Boston Scientific Corporation alert may contain errors. Disclosures
Lawmaker Discloses Healthcare Investment
Representative Gilbert Cisneros, a Democrat serving California's 31st district in the U.S. House, recently disclosed a purchase of Boston Scientific Corporation (BSX) stock. The transaction, which took place on May 29, 2026, involved an amount between $1,001 and $15,000. This trade was revealed through a periodic transaction report filed under the STOCK Act and became public on June 9, 2026.
Cisneros' move follows other notable political interest in the healthcare giant. In the weeks prior, former President Donald Trump also acquired a stake in the company. These disclosures provide a window into the personal portfolios of public officials, though the law requires these reports only after the trades have already been completed.
Gilbert Cisneros vs. the S&P 500
Hypothetical returns from Gilbert Cisneros's disclosed trades, not real profit or advice. How we model this.
Boston Scientific Stock Performance
On Saturday, Boston Scientific shares were priced at $42.84. This puts the stock quite close to its 52-week low of $41.39, a sharp contrast to the high of $105.65 seen earlier in the year. The company currently has a P/E ratio of 17.87, which is a common way for investors to value a stock by comparing its price to its earnings. When looking ahead at expected profits, the forward P/E is slightly lower at 13.07.
Financial Health and Recent Earnings
In its most recent financial reports, Boston Scientific showed steady growth with revenue reaching $20.99 billion, a 7.5% increase. The company is profitable, posting an earnings per share (EPS) of $2.47. It also maintains a healthy return on equity (ROE) of 15.3%, which measures how effectively the company uses shareholder money to generate profit. The next time the company will update the public on its financial progress is scheduled for October 28, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
12 target cuts vs 1 raises.
-
EPS & revenue
EPS beat estimates by 0.7%. Revenue met estimates.
-
Profit surprise
EBITDA met by 0 percent. Operating income missed by 13 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
1 target raise, 12 target cuts.
-
Earnings quality
Gross margin up 6.2 points. Operating margin up 1.4 points. Positive free cash flow.
Earnings Call Summary
Boston Scientific reported first quarter sales of $5.2 billion, up 9.4 percent, and beat on earnings at $0.80 per share. However, management revealed major headwinds in three key franchises. The EP cardiology ablation business, which grew 22 percent this quarter, is now expected to slow to 10 percent full year as competition from Medtronic, J and J, and Abbott pressures U.S. share. WATCHMAN, which grew 19 percent, slowed sharply in February as stand-alone procedures fell even as concomitant adoption grew. Urology nearly flatlined at 1 percent growth due to problems in stone management and sacral neuromodulation. Management said the company lost more market share than expected and hospital capacity constraints are limiting WATCHMAN procedure volume.
Guidance The company cut its full year sales growth guidance from an expected 8 to 10 percent range down to 6.5 to 8 percent. They expect second quarter sales to grow only 5 to 7 percent year over year. The company now guides full year earnings per share to $3.34 to $3.41, still up 9 to 11 percent but well below prior expectations.
Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.
Wall Street Analyst Views
Professional analysts have been busy adjusting their expectations for the medical device firm. On October 14, 2026, Truist Securities maintained its Buy rating but lowered its price target to $51.00. Earlier in the month, Barclays initiated coverage with an Equal-Weight rating and a $48.00 target. Other firms like Oppenheimer and BTIG also remain positive, with price targets ranging from $56.00 to $65.00. Overall, the consensus among 29 analysts is a Buy, with an average target price of $59.24.
About Boston Scientific
Boston Scientific creates and sells a wide variety of medical equipment used in hospitals and clinics. Their products range from heart stents and pacemakers to tools for treating urological and neurological conditions. Because the company touches so many parts of the healthcare system, it is often seen as a bellwether for the broader medical technology industry.
What's Ahead for Boston Scientific Corporation
Investors will likely watch for the company's October earnings report to see if its revenue growth can pick up speed. While congressional trades like the one from Cisneros are interesting to track, they are backward-looking and do not necessarily mean the lawmaker still holds the shares today or that the trade was based on non-public information. This report is for informational purposes and is not a recommendation to buy or sell.
Related Filing Alerts
Source: Gilbert Cisneros's STOCK Act disclosure on $BSX (May 29, 2026). Find the original filing: House financial disclosure search. Written by software, not financial advice. How we make alerts